The BGI reverse transcriptase real-time Fluorescent PCR kit for detecting SARS-CoV-2 enables the detection of the virus in just 3 hours. The kit is a qualitative in vitro nucleic acid amplification assay used to detect SARS-CoV-2 using reverse transcription PCR from throat swab and Bronchoalveolar Lavage Fluid(BALF)samples. The test primers are derived from the first SARS-CoV-2 RNA sequences (orf1ab) identified in Wuhan. The test has a high specificity and displays no cross reaction with any of the following strains: OC43, 229E, HKU1, NL63 (hcov-oc43, hcov-229e, HCoVHKU1, hcov-nl63) or other virus types. With a detection limit of 100 copies /mL it is also highly sensitive.
Whole-Process Quality Control: An internal (endogenous) control is included to monitor the complete process from sample taking, nucleic acid extraction, reverse transcription and to amplification for each individual sample.
Whole-Process Quality Control: An internal control was set to monitor the laboratory procedures including nucleic acid extraction, Revert transcription and amplification in each reaction.